PF-06372865

Phase 2Small molecule

Pfizer

PF-06372865 is one of 88 small molecule programs targeting Low back pain. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Low Back PainActive, not recruiting

Photosensitive EpilepsyActive, not recruiting

Generalized Anxiety DisorderActive, not recruiting

Low Back PainPhase 2

Active, not recruiting

Photosensitive EpilepsyPhase 2

Active, not recruiting

Generalized Anxiety DisorderPhase 2

Active, not recruiting

Competition

Competitive Landscape

237 competitors in Low Back Pain

#DrugCompanyPhaseTrials

Arcoxia

Novartis

Phase 3

1 2

Sympazan

Lundbeck

Phase 3

1 3

Suboxone

IIndivior Inc.

Phase 3

4 4

Tylenol

KKenvue Brands

Phase 3

3 5

Anjeso

Boehringer Ingelheim

Phase 3

1 6

Amoxil

GGlobal Antibiotics Research and Development Partnership

Phase 3

1 7

Xylocaine

MMEDRx USA, Inc.

Phase 3

1 8

Circadin

NNeurim Pharmaceuticals Ltd.

Phase 3

1 9

Hydrocodone/acetaminophen

AbbVie

Phase 3

2 10

Oxycodone CR

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Oral1 trial

A Study to Examine the Distribution of PF-06372865 in the Brain of Healthy Volunteers Using Positron Emission Tomography and a Radioactive Tracer Following Oral Administration of One Dose of PF-06372865

Completed· Pfizer logo

Pfizer·Phase 1·NCT02138500·5 enrolled

Tics1 trial

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Repeat Doses of PF-06372865 in Healthy Subjects

Completed· Pfizer logo

Pfizer·Phase 1·NCT03351751·19 enrolled

Photosensitive Epilepsy1 trial

PF-06372865 in Subjects With Photosensitive Epilepsy

Completed· Pfizer logo

Pfizer·Phase 2·NCT02564029·7 enrolled

Low back pain1 trial

PF-06372865 In Subjects With Chronic Low Back Pain

Completed· Pfizer logo

Pfizer·Phase 2·NCT02262754·302 enrolled

Generalized Anxiety Disorder1 trial

POC Study in Partially Responsive Generalized Anxiety Disorder

Terminated· Pfizer logo

Pfizer·Phase 2·NCT02310568·90 enrolled

3 more indications

Analgesic1 trial

Assessment of the Analgesic Effects of PF-06372865 in Healthy Volunteers Using Evoked Pain Endpoints

Completed· Pfizer logo

Pfizer·Phase 1·NCT02238717·20 enrolled

Concentration1 trial

A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06372865 in Healthy Subjects of Two AgeGroups, Aged 18-55 Years (Group 1) and Aged 56-75 Years (Group 2)

Completed· Pfizer logo

Pfizer·Phase 1·NCT02070289·50 enrolled

Unspecified2 trials

Food Effect Study for PF-06372865

Completed· Pfizer logo

Pfizer·Phase 1·NCT02217787·12 enrolled

An Open-label, Two-period, Fixed-sequence Study to Evaluate Multiple-dose Itraconazole Effect on The Single-dose PK of PF-06372865 in Healthy Subjects

Withdrawn· Pfizer logo

Pfizer·Phase 1·NCT02475746

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for PF-06372865. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PF-06372865 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PF-06372865. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Pfizer

PF-06372865

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Oral1 trial

Tics1 trial

Photosensitive Epilepsy1 trial

Low back pain1 trial

Generalized Anxiety Disorder1 trial

Analgesic1 trial

Concentration1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News